Seres Therapeutics appoints Claire Fraser, Ph.D. as Class II director and to Audit Committee

Seres Therapeutics, Inc.

Board expanded to ten directors; Dr. Fraser appointed as Class II director and to Audit Committee.
Standard non-employee director compensation: $45,000 annual retainer, $10,000 audit committee retainer.
Initial option grant: 48,000 shares at $5.47 exercise price, vesting over four years or upon change in control.
Entered into standard director and officer indemnification agreement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Claire Fraser

Class II Director

MCRB · Seres Therapeutics, Inc.

Effective: 2023-01-04
Filed: January 5, 2023, 6:59 PM ET

On January 4, 2023, the Board of Directors (the “Board”) of Seres Therapeutics, Inc. (the “Company”) increased its size to provide for a total of ten directors authorized to serve on the Board and appointed Claire Fraser, Ph.D. as a Class II director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Claire Fraser was appointed as Class II Director at Seres Therapeutics, Inc..

Action: appointed
Role: Class II Director

Exact text from the filing

On January 4, 2023, the Board of Directors (the “Board”) of Seres Therapeutics, Inc. (the “Company”) increased its size to provide for a total of ten directors authorized to serve on the Board and appointed Claire Fraser, Ph.D. as a Class II director of the Company.

View on SEC.gov

Seres Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-002405

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.